Recent progress in pathophysiology of cortisol-producing adrenal tumor
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations of the PRKACA gene have been linked to Cushing’s syndrome (26), cardiomyopathies, and more recently, to impaired Hedgehog signaling that leads to Cardioacrofacial Dysplasia (CAFD) (27, 28).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566 · cited 2×
“…review focuses on recent developments in cortisol-producing adrenal tumors including Cushing’s syndrome (CS) [1] and mild autonomous cortisol secre‐ tion (MACS) [2], also termed subclinical CS (SCS) [3], with particular emphasis on major advances in under‐ standing their molecular pathogenesis [4].”
OMURA, M., SAITO, J., YAMAGUCHI, K., KAKUTA, Y., & NISHIKAWA, T. (2004) · Hypertension Research · doi:10.1291/hypres.27.193 · Cited by 562 · cited 1×
“The frequency of CS in common dis‐ eases has been reported as 0.6–1% in hypertension [19], 0.2–0.6% in patients with diabetes mellitus and a BMI ≥25 [20], and about 0.2% in obese or metabolic syn‐ drome patients with a BMI ≥30 [21].”
InfluentialTissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474 · cited 2×
“Interestingly, CTNNB1 mutations in the Wnt-β-catenin signaling pathways are rare in CS but rel‐ atively common in MACS [54, 57] and non-functioning adrenal adenomas (NFA) [56].”
Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome
Beuschlein, F., Fassnacht, M., Assié, G., Calebiro, D., Stratakis, C. A., Osswald, A., Ronchi, C. L., Wieland, T., Sbiera, S., Faucz, F. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310359 · Cited by 443
ARMC5 Mutations in Macronodular Adrenal Hyperplasia with Cushing's Syndrome
Assié, G., Libé, R., Espiard, S., Rizk-Rabin, M., Guimier, A., Luscap, W., Barreau, O., Lefèvre, L., Sibony, M., Guignat, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304603 · Cited by 395 · cited 1×
“In 2013, germline loss-of-function mutations in the tumor suppressor gene armadillo repeat containing 5 ( ARMC5 ) were identified in 55% of PBMAH cases, with loss of heterozygosity (LOH), establishing ARMC5 as the main causative gene [39].”
Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
Arlt, W., Lang, K., Sitch, A. J., Dietz, A. S., Rhayem, Y., Bancos, I., Feuchtinger, A., Chortis, V., Gilligan, L. C., Ludwig, P., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93136 · Cited by 281
Recurrent somatic mutations underlie corticotropin-independent Cushing’s syndrome
Sato, Y., Maekawa, S., Ishii, R., Sanada, M., Morikawa, T., Shiraishi, Y., Yoshida, K., Nagata, Y., Sato-Otsubo, A., Yoshizato, T., et al. (2014) · Science · doi:10.1126/science.1252328 · Cited by 209
Bonnet, S., Gaujoux, S., Launay, P., Baudry, C., Chokri, I., Ragazzon, B., Libé, R., René-Corail, F., Audebourg, A., Vacher-Lavenu, M.-C., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1885 · Cited by 133
EMRAL, R., UYSAL, A. R., ASIK, M., GULLU, S., CORAPCIOGLU, D., TONYUKUK, V., & ERDOGAN, G. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.399 · Cited by 104 · cited 1×
“Supporting this, cases of NFATs show a higher rate of improvement in glucose tolerance and hypertension after surgical removal compared to non-surgical cases [62-65].”
Yanase, T., Oki, Y., Katabami, T., Otsuki, M., Kageyama, K., Tanaka, T., Kawate, H., Tanabe, M., Doi, M., Akehi, Y., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej17-0456 · Cited by 90
Self-citation
Research works printed but not linked: 66
- 1 Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing’s syndrome. Lancet 386: 913–927. · DOI · Paper page
- 4 Pitsava G, Stratakis CA (2022) Genetic alterations in benign adrenal tumors. Biomedicines 10: 1041. · DOI
- 5 Goto T, Takata T, Sato E, Tamura K, Yanase T (2013) A case of acute respiratory distress syndrome caused by cryptococcus and cytomegalovirus co-infection after Cushing’s syndrome treatment. Kansensyogakuzassi 87: 39–43 (In Japanese). · DOI
- 6 Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, et al. (2016) Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4: 569–576. · DOI · Paper page
- 7 Hakami OA, Ahmed S, Karavitaki N (2021) Epidemiology and mortality of Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 35: 101521. · DOI
- 9 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, et al. (2008) The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526–1540. · DOI · Paper page
- 10 Katabami T, Asai S, Matsuba R, Sone M, Izawa S, et al. (2025) Changes in clinical features of adrenal Cushing syndrome: a national registry study. Endocr Connect 14: e240684. · DOI
- 11 Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, et al. (2020) Time to diagnosis in Cushing’s syndrome: a meta-analysis based on 5367 patients. J Clin Endocrinol Metab 105: dgz136. · DOI · Paper page
- 12 Kreitschmann-Andermahr I, Psaras T, Tsiogka M, Starz D, Kleist B, et al. (2015) From first symptoms to final diagnosis of Cushing’s disease: experiences of 176 patients. Eur J Endocrinol 172: 285–289. · DOI · Paper page
- 13 Limumpornpetch P, Morgan AW, Tiganescu A, Baxter PD, Nyawira Nyaga V, et al. (2022) The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality. J Clin Endocrinol Metab 107: 2377–2388. · DOI · Paper page
- 14 Loriaux DL (2017) Diagnosis and differential diagnosis of Cushing’s syndrome. N Engl J Med 376: 1451–1459. · DOI · Paper page
- 16 Kelly W (1996) Exophthalmos in Cushing’s syndrome. Clin Endocrinol (Oxf) 45: 167–170. · DOI
- 17 Panzer SW, Patrinely JR, Wilson HK (1994) Exophthalmos and iatrogenic Cushing’s syndrome. Ophthalmic Plast Reconstr Surg 10: 278–282. · DOI
- 18 Braun LT, Vogel F, Zopp S, Marchant Seiter T, Rubinstein G, et al. (2022) Whom should we screen for Cushing syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. J Clin Endocrinol Metab 107: e3723–e3730. · DOI · Paper page
- 21 Atar RV, Yildiz I, Topcu B, Elbuken G, Zuhur SS (2020) The frequency of Cushing’s disease, ACTH-independent Cushing’s syndrome and autonomous cortisol secretion among Turkish patients with obesity. North Clin Istanb 7: 214–221. · DOI
- 23 Akehi Y, Kawate H, Murase K, Nagaishi R, Nomiyama T, et al. (2013) Proposed diagnostic criteria for subclinical Cushing’s syndrome associated with adrenal incidentaloma. Endocr J 60: 903–912. · DOI
- 24 Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Savoca C, et al. (2010) Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf) 73: 161–166. · DOI · Paper page
- 25 Ichijo T, Ueshiba H, Nawata H, Yanase T (2020) A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J 67: 141–152. · DOI
- 26 Yanase T, Fujieda K, Kajieda H, Tanahashi Y, Suzuki S (2011) A nationwide epidemiological study of Addison’s disease and subclinical Cushing’s disease. Annual report of Intractable Disease Research Grant of Ministry of Health, Labour and Welfare, Japan “Research on Adrenal Hormone Disorders 2010”: 117–124 (In Japanese).
- 27 Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, et al. (2014) Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 99: 4462–4470. · DOI · Paper page
- 28 Favero V, Cremaschi A, Parazzoli C, Falchetti A, Gaudio A, et al. (2022) Pathophysiology of mild hypercortisolism: from the bench to the bedside. Int J Mol Sci 23: 673. · DOI
- 29 Tabuchi Y, Otsuki M, Kasayama S, Kosugi K, Hashimoto K, et al. (2016) Clinical and endocrinological characteristics of adrenal incidentaloma in Osaka region, Japan. Endocr J 63: 29–35. · DOI
- 30 Abe I, Sugimoto K, Miyajima T, Ide T, Minezaki M, et al. (2018) Clinical investigation of adrenal incidentalomas in Japanese patients of the Fukuoka region with updated diagnostic criteria for sub-clinical Cushing’s syndrome. Intern Med 57: 2467–2472. · DOI
- 31 Aoe M, Okada A, Usui T, Manaka K, Nangaku M, et al. (2020) Comparison between the clinical characteristics of patients with adrenal incidentalomas and those with hypertension-associated adrenal tumors in a single center in Japan. Endocr J 67: 645–654. · DOI
- 33 Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, et al. (2019) High prevalence of diabetes in patients with Primary Aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large, multicenter cohort study in Japan. Diabetes Care 42: 938–945. · DOI · Paper page
- 34 Yokomoto-Umakoshi M, Sakamoto R, Umakoshi H, Matsuda Y, Nagata H, et al. (2020) Unilateral primary aldosteronism as an independent risk factor for vertebral fracture. Clin Endocrinol (Oxf) 92: 206–213. · DOI
- 35 Yokomoto-Umakoshi M, Fujita M, Umakoshi H, Ogasawara T, Iwahashi N, et al. (2025) Multiomics analysis unveils the cellular ecosystem with clinical relevance in aldosterone-producing adenomas with KCNJ5 mutations. Proc Natl Acad Sci U S A 122: e2421489122. · DOI
- 36 Louiset E, Lefebvre H (2014) Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 370: 1071–1072. · doi:10.1056/nejmc1316140
- 37 Cavalcante IP, Berthon A, Fragoso MC, Reincke M, Stratakis CA, et al. (2022) Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease. Nat Rev Endocrinol 18: 699–711. · DOI
- 38 Bertherat J, Bourdeau I, Bouys L, Chasseloup F, Kamenický P, et al. (2023) Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia. Endocr Rev 44: 567–628. · DOI
- 40 Chevalier B, Vantyghem MC, Espiard S (2021) Bilateral adrenal hyperplasia: pathogenesis and treatment. Biomedicines 9: 1397. · DOI
- 41 Stratakis CA, Berthon A (2019) Molecular mechanisms of ARMC5 mutations in adrenal pathophysiology. Curr Opin Endocr Metab Res 8: 104–111. · DOI
- 42 Okuno Y, Fukuhara A, Otsuki M, Shimomura I (2022) ARMC5-CUL3 E3 ligase targets full-length SREBF in adrenocortical tumors. JCI Insight 7: e151390. · DOI
- 43 Chasseloup F, Bourdeau I, Tabarin A, Regazzo D, Dumontet C, et al. (2021) Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes Endocrinol 9: 813–824. · DOI
- 44 Vaczlavik A, Bouys L, Violon F, Giannone G, Jouinot A, et al. (2022) KDM1A inactivation causes hereditary food-dependent Cushing syndrome. Genet Med 24: 374–383. · DOI
- 45 Elhassan YS, Appenzeller S, Landwehr LS, Lippert J, Popat D, et al. (2024) Primary unilateral macronodular adrenal hyperplasia with concomitant glucocorticoid and androgen excess and KDM1A inactivation. Eur J Endocrinol 191: 334–344. · DOI
- 47 Cao Y, He M, Gao Z, Peng Y, Li Y, et al. (2014) Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome. Science 344: 913–917. · DOI · Paper page
- 49 Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, et al. (2014) Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet 46: 613–617. · DOI · Paper page
- 50 Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, et al. (2014) Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing’s syndrome: a European multicentric study. J Clin Endocrinol Metab 99: E2093–E2100. · DOI · Paper page
- 51 Nakajima Y, Okamura T, Gohko T, Satoh T, Hashimoto K, et al. (2014) Somatic mutations of the catalytic subunit of cyclic AMP-dependent protein kinase (PRKACA) gene in Japanese patients with several adrenal adenomas secreting cortisol [Rapid Communication]. Endocr J 61: 825–832. · DOI · Paper page
- 52 Higuchi S, Komai E, Fujimoto M, Tamura A, Shiga A, et al. (2015) Research on PRKACA mutation/gene expression in 120 cases with SCS. Folia Endocrinologica Japonica 91 (Suppl. Update): 30–33 (In Japanese). · DOI
- 53 Baba R, Oki K, Gomez-Sanchez CE, Otagaki Y, Itcho K, et al. (2021) Genotype-specific cortisol production associated with Cushing’s syndrome adenoma with PRKACA mutations. Mol Cell Endocrinol 538: 111456. · DOI
- 54 Rege J, Hoxie J, Liu CJ, Cash MN, Luther JM, et al. (2022) Targeted mutational analysis of cortisol-producing adenomas. J Clin Endocrinol Metab 107: e594–e603. · DOI
- 55 Calebiro D, Hannawacker A, Lyga S, Bathon K, Zabel U, et al. (2014) PKA catalytic subunit mutations in adrenocortical Cushing’s adenoma impair association with the regulatory subunit. Nat Commun 5: 5680. · DOI · Paper page
- 57 Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assié G, et al. (2016) Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation. J Clin Endocrinol Metab 101: 3526–3538. · DOI · Paper page
- 59 Di Dalmazi G, Altieri B, Scholz C, Sbiera S, Luconi M, et al. (2020) RNA sequencing and somatic mutation status of adrenocortical tumors: novel pathogenetic insights. J Clin Endocrinol Metab 105: dgaa616. · doi:10.1530/endoabs.70.yi3
- 61 Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, et al. (2019) Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med 171: 107–116. · DOI · Paper page
- 62 Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, et al. (2000) Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 85: 1440–1448. · doi:10.1210/jcem.85.4.6515 · Paper page
- 63 Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, et al. (2010) Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95: 2736–2745. · DOI · Paper page
- 64 Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T (2001) The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 54: 797–804. · DOI · Paper page
- 66 Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, et al. (2016) “Nonfunctional” adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann Intern Med 165: 533–542. · DOI · Paper page
- 67 Fukumoto T, Umakoshi H, Iwahashi N, Ogasawara T, Yokomoto-Umakoshi M, et al. (2024) Steroids-producing nodules: a two-layered adrenocortical nodular structure as a precursor lesion of cortisol-producing adenoma. EBioMedicine 103: 105087. · DOI
- 68 Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM (2022) Primary aldosteronism: state-of-the-art review. Am J Hypertens 35: 967–988. · DOI
- 69 Youssef J, Novosad SA, Winthrop KL (2016) Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 42: 157–176, ix–x. · DOI · Paper page
- 70 Sieber SC, Dandurand R, Gelfman N, Iannini P, Braza F (1989) Three opportunistic infections associated with ectopic corticotropin syndrome. Arch Intern Med 149: 2589–2591. · DOI
- 71 Kim DS, Park SK, Choi WH, Kim TW, Choi YY, et al. (2000) Pneumocystis carinii pneumonia associated with a rapid reduction of cortisol level in a patient with ectopic ACTH syndrome treated by octreotide and ketoconazole. Exp Clin Endocrinol Diabetes 108: 146–150. · DOI
- 73 Arlt A, Harbeck B, Anlauf M, Alkatout I, Klöppel G, et al. (2008) Fatal pneumocystis jirovecii pneumonia in a case of ectopic Cushing’s syndrome due to neuroendocrine carcinoma of the kidney. Exp Clin Endocrinol Diabetes 116: 515–519. · DOI
- 74 Gabalec F, Zavrelová A, Havel E, Cerman J Jr, Radocha J, et al. (2011) Pneumocystis pneumonia during medicamentous treatment of Cushing’s syndrome—a description of two cases. Acta Medica (Hradec Kralove) 54: 127–130. · doi:10.14712/18059694.2016.35
- 75 van Halem K, Vrolijk L, Pereira AM, de Boer MGJ (2017) Characteristics and mortality of Pneumocystis pneumonia in patients with Cushing’s syndrome: a plea for timely initiation of chemoprophylaxis. Open Forum Infect Dis 4: ofx002. · DOI
- 76 Tan L, Zhao L, Tang G, Ren Y, Tian H, et al. (2023) Unexpected exacerbation of cryptococcal meningitis after unilateral adrenalectomy in a PMAH patient: a case report and literature review. BMC Endocr Disord 23: 199. · doi:10.1186/s12902-023-01457-5
- 79 Ohba D, Okamoto Y, Miyamoto U, Takeda Y, Terazaki Y, et al. (2023) Ectopic ACTH-producing pulmonary typical carcinoid with pneumocystic pneumonia after lobectomy: a case report. JJLC 63: 182–187 (Abstract in English). · DOI
- 80 Brienze VMS, André JC, Liso E, Louis IV (2021) Cryptococcal immune reconstitution inflammatory syndrome: from blood and cerebrospinal fluid biomarkers to treatment approaches. Life (Basel) 11: 95. · DOI
- 81 Shimatsu A, Biller BM, Fleseriu M, Pivonello R, Lee EJ, et al. (2024) Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4). Endocr J 71: 1103–1123. · DOI
- 82 Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, et al. (2020) A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease. Endocr J 67: 841–852. · DOI · Paper page
- 83 Igaz P, Tömböl Z, Szabó PM, Likó I, Rácz K (2008) Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem 15: 2734–2747. · DOI · Paper page
- 84 Detomas M, Altieri B, Deutschbein T, Fassnacht M, Dischinger U (2022) Metyrapone versus osilodrostat in the short-term therapy of endogenous Cushing’s syndrome: results from a single center cohort study. Front Endocrinol (Lausanne) 13: 903545. · DOI
Cited by
Bruystens, J. G. H., Wu, J., Tan, G., Bertinetti, D., Zenn, H.-M., Zimmermann, B., Chen, L., Köckenberger, J., Massaro, F., Sankaran, B., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536312123 · Cited by 3
Metadata
- Authors
- Yanase, T.
- Affiliations
- Seiwakai Muta Hospital, Fukuoka 814-0163, Japan
- ORCID
- Yanase, Toshihiko
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2026
- Volume
- 73
- Issue
- 1
- Pages
- 1-12
- ISSN
- 0918-8959
- 1348-4540
- Cited by
- 6
- References
- 11
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.